野生型胃肠道间质瘤的研究进展

doi:10.11904/j.issn.1002-3070.2020.06.008

摘要/Abstract

摘要： 胃肠道间质瘤(GIST)是最常见的消化道间叶组织来源肿瘤,约10%的GIST患者分子检测无KIT/PDGFRA基因突变,称为野生型GIST。根据是否有琥珀酸脱氢酶B(SDHB)表达缺失,野生型GIST可分为SDH缺陷型和非SDH缺陷型,SDH缺陷型包括无综合征相关性、Carney三联征相关性及Carney-stratakis综合征相关性GIST;非SDH缺陷型包括BRAF突变、Ⅰ型神经纤维瘤病相关性、K/N-RAS突变及四重野生型GIST等。野生型GIST的发生发展、临床病理特征和治疗原则均与KIT或PDGFRA突变的GIST有较大差异。本文就野生型GIST的分子机制和临床诊疗进展做一综述。

关键词: 野生型胃肠道间质瘤, 琥珀酸脱氢酶, 诊断, 治疗

Abstract: Gastrointestinal stromal tumor(GIST)is the most common tumor of archenteric mesenchymal tissue.About 10% of patients are diagnosed as GIST morphologically and immunohistochemically without KIT and PDGFRA gene mutations which is defined wild-type GIST.According to the absence of succinate dehydrogenase B(SDHB)expression,wild-type GIST can be divided into SDH-deficient and non-SDH-deficient types.SDH-deficient types include syndrome-free associated,Carney triad associated,and Carney-stratakis synthesis associated GIST;non-SDH-deficient types include BRAF mutations,type I neurofibromatosis-related,K/N-RAS mutations,and quadruple wild-type GIST.The occurrence,development,clinicopathological features and treatment principles of wild-type GIST are significantly different from those of KIT or PDGFRA mutant GIST.This article reviews the molecular mechanism and clinical progress of wild-type GIST.

Key words: Wild-type gastrointestinal stromal tumor, Succinate dehydrogenase(SDH), Diagnosis, Treatment

中图分类号:

735.2

白怡冰, 杨佳妮, 方琳, 张艳桥. 野生型胃肠道间质瘤的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 524-529.

BAI Yibing, YANG Jiani, FANG Lin, ZHANG Yanqiao. Research progress of wild-type gastrointestinal stromal tumors[J]. Journal of Practical Oncology, 2020, 34(6): 524-529.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.06.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I6/524

参考文献

1 Corless CL,Barnett CM,Heinrich MC.Gastrointestinal stromal tumours:origin and molecular oncology[J].Nat Rev Cancer,2011,11(12):865-878.
2 Wang TN,Yao WM.Analysis of pathological characteristics,diagnosis and treatment of gastrointestinal stromal tumors[J].Practical Oncology Journal,2008,22(4):326-327.
3 Li J,Ye Y,Wang J,et al.Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor[J].Chin J Cancer Res,2017,29(4):281-293.
4 Wada R,Arai H,Kure S,et al.“Wild type”GIST:clinicopathological features and clinical practice[J].Pathol Int,2016,66(8):431-437.
5 Astolfi A,Nannini M,Pantaleo MA,et al.A molecular portrait of gastrointestinal stromal tumors:an integrative analysis of gene expression profiling and high-resolution genomic copy number[J].Lab Invest,2010,90(9):1285-1294.
6 Jasek K,Buzalkova V,Minarik G,et al.Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors[J].Virchows Arch,2017,470(1):29-36.
7 Belinsky MG,Cai KQ,Zhou Y,et al.Succinate dehydrogenase deficiency in a PDGFRA mutated GIST[J].BMC Cancer,2017,17(1):512.
8 Bardella C,Pollard PJ,Tomlinson I.SDH mutations in cancer[J].Biochim Biophys Acta,2011,1807(11):1432-1443.
9 Belinsky MG,Rink L,von Mehren M.Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors[J].Front Oncol,2013,3:117.
10 Boikos SA,Pappo AS,Killian JK,et al.Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors:a report from the national institutes of health gastrointestinal stromal tumor clinic[J].JAMA Oncology,2016,2(7):922-928.
11 Tarn C,Rink L,Merkel E,et al.Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors[J].Proc Natl Acad Sci U S A,2008,105(24):8387-8392.
12 Nannini M,Astolfi A,Paterini P,et al.Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction[J].Future oncology(London,England),2013,9(1):121-126.
13 Flavahan WA,Drier Y,Johnstone SE,et al.Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs[J].Nature,2019,575(7781):229-233.
14 Janeway KA,Kim SY,Lodish M,et al.Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations[J].Proc Natl Acad Sci U S A,2011,108(1):314-318.
15 Doyle LA,Nelson D,Heinrich MC,et al.Loss of succinate dehydrogenase subunit B(SDHB)expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours:a comprehensive genotype-phenotype correlation study[J].Histopathology,2012,61(5):801-809.
16 Oudijk L,Gaal J,Korpershoek E,et al.SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors[J].Mod Pathol,2013,26(3):456-463.
17 Pantaleo MA,Astolfi A,Urbini M,et al.Analysis of all subunits,SDHA,SDHB,SDHC,SDHD,of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST[J].Eur J Hum Genet,2014,22(1):32-39.
18 Settas N,Faucz FR,Stratakis CA.Succinate dehydrogenase(SDH)deficiency,Carney triad and the epigenome[J].Mol Cell Endocrinol,2018,469:107-111.
19 Agaimy A,Terracciano LM,Dirnhofer S,et al.V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours[J].J Clin Pathol,2009,62(7):613-616.
20 Daniels M,Lurkin I,Pauli R,et al.Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors(GIST)[J].Cancer Lett,2011,312(1):43-54.
21 Franck C,Rosania R,Franke S,et al.The BRAF status may predict response to sorafenib in gastrointestinal stromal tumors resistant to imatinib,sunitinib,and regorafenib:case series and review of the literature[J].Digestion,2019,99(2):179-184.
22 Shang L,Fang Z,Liu J,et al.Case report of ascending colon cancer and multiple jejunal GISTs in a patient with neurofibromatosis type 1(NF1)[J].BMC Cancer,2019,19(1):1196.
23 Miranda C,Nucifora M,Molinari F,et al.KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors[J].Clin Cancer Res,2012,18(6):1769-1776.
24 Lasota J,Xi L,Coates T,et al.No KRAS mutations found in gastrointestinal stromal tumors(GISTs):molecular genetic study of 514 cases[J].Mod Pathol,2013,26(11):1488-1491.
25 Nannini M,Astolfi A,Urbini M,et al.Integrated genomic study of quadruple-WT GIST(KIT/PDGFRA/SDH/RAS pathway wild-type GIST)[J].BMC Cancer,2014,14:685.
26 Brenca M,Rossi S,Polano M,et al.Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST[J].J Pathol,2016,238(4):543-549.
27 Shi E,Chmielecki J,Tang CM,et al.FGFR1 and NTRK3 actionable alterations in“Wild-Type”gastrointestinal stromal tumors[J].J Transl Med,2016,14(1):339.
28 Nannini M,Urbini M,Astolfi A,et al.The progressive fragmentation of the KIT/PDGFRA wild-type(WT)gastrointestinal stromal tumors(GIST)[J].J Transl Med,2017,15(1):113.
29 Pantaleo MA,Urbini M,Indio V,et al.Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in quadruple WT GIST[J].Molecular Cancer Research,2017,15(5):553-562.
30 Urbini M,Indio V,Tarantino G,et al.Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST[J].Genes Chromosomes Cancer,2019,58(9):636-642.
31 Weldon CB,Madenci AL,Boikos SA,et al.Surgical management of wild-type gastrointestinal stromal tumors:a report from the national institutes of health pediatric and wildtype GIST clinic[J].J Clin Oncol,2017,35(5):523-528.
32 Ben-Ami E,Barysauskas CM,von Mehren M,et al.Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy[J].Ann Oncol,2016,27(9):1794-1799.
33 Schroeder BA,Kohli K,O′Malley RB,et al.Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab[J].Oncoimmunology,2020,9(1):1710064.
34 Mir O,Cropet C,Toulmonde M,et al.Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib(PAZOGIST):a randomised,multicentre,open-label phase 2 trial[J].The Lancet Oncology,2016,17(5):632-641.
35 Falchook GS,Trent JC,Heinrich MC,et al.BRAF mutant gastrointestinal stromal tumor:first report of regression with BRAF inhibitor dabrafenib(GSK2118436)and whole exomic sequencing for analysis of acquired resistance[J].Oncotarget,2013,4(2):310-315.
36 von Mehren M,George S,Heinrich MC,et al.Linsitinib(OSI-906)for the treatment of adult and pediatric wild-type gastrointestinal stromal tumors,a SARC Phase II Study[J].Clin Cancer Res,2020,26(8):1837-1845.
37 Glod J,Arnaldez FI,Wiener L,et al.A phase II trial of vandetanib in children and adults with succinate dehydrogenase-deficient gastrointestinal stromal tumor[J].Clin Cancer Res,2019,25(21):6302-6308.
38 Liu F,Zou F,Chen C,Yu K,et al.Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors[J].Ther Adv Med Oncol,2019,11:1758835919849757.

[1]	左蕊, 金路, 刘丽, 刘小嘉, 赵鹏宇, 向小燕. miR-409-3p在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 554-559.
[2]	石琳娜, 隋红. 原发性肝癌免疫检查点抑制剂治疗的进展与挑战[J]. 实用肿瘤学杂志, 2020, 34(6): 560-564.
[3]	宋家羽, 冯越, 王棹, 张云艳. 外泌体与妇科恶性肿瘤相关性的最新研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 571-575.
[4]	卢江岳, 张建鑫, 葛晓峰. 鼻咽癌同步推量同步放化疗与常规分割后缩野同步放化疗的疗效及毒性反应对比分析[J]. 实用肿瘤学杂志, 2020, 34(5): 440-445.
[5]	李爽, 金世柱. 人工智能在内镜诊断上消化道早癌领域的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 471-475.
[6]	赵颖欣, 秦玲. 二甲双胍与多发性骨髓瘤的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 476-479.
[7]	李恒震, 张艳桥. 液体活检在结直肠癌诊断中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(4): 357-361.
[8]	张锐, 李志高. 粘液性乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 377-381.
[9]	邓俊, 袁媛, 罗璇, 谭惜颜, 于恩浩, 刘科, 吴崢, 周菊梅, 朱苏雨. 化放疗模式下早期弥漫大B细胞淋巴瘤缩小放疗野对生存预后的影响[J]. 实用肿瘤学杂志, 2020, 34(3): 237-243.
[10]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[11]	李慧, 庞达. 三阳型乳腺癌的临床病理学特点及辅助治疗[J]. 实用肿瘤学杂志, 2020, 34(3): 262-265.
[12]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.
[13]	鲁雪梅, 李云涛, 安锦慧, 季国忠. 溶血磷脂酸在结直肠癌发生发展中的机制研究[J]. 实用肿瘤学杂志, 2020, 34(3): 276-281.
[14]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[15]	苏文佳, 王树叶. 滤泡性淋巴瘤的预后分层和治疗进展[J]. 实用肿瘤学杂志, 2020, 34(2): 189-192.